Shaymaa Azawi1, Martina Rincic2, Thomas Liehr3. 1. Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Am Klinikum 1, 07747, Jena, Germany. 2. Croatian Institute for Brain Research, School of Medicine University of Zagreb, Salata 12, 10000, Zagreb, Croatia. 3. Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Am Klinikum 1, 07747, Jena, Germany. Thomas.Liehr@med.uni-jena.de.
Abstract
BACKGROUND: Breast cancer (BC), one of the most frequent human tumors, is genetically and histologically heterogeneous. Treatment options can be adapted according to BC subtype. Still, research is necessary to characterize BC biology better and to study potential new treatment options. Murine BC-cell lines can be used as model systems in this respect. RESULTS: Here for the first time murine BC-cell line JC was cytogenomically characterized as being complex rearranged and near-tetraploid. Multicolor banding and array comparative genomic hybridization were applied and the result was in silico translated to the human genome. CONCLUSIONS: Even though being commercially available, cell line JC was yet not much included in BC-research, most likely due to a lack of cytogenomic data. Thus, here comprehensive data is provided on chromosomal aberrations, genomic imbalances and involved breakpoints of JC cell line. Also JC could be characterized as a model for BC of luminal B type, basal-like tumor rather than for luminal A type.
BACKGROUND:Breast cancer (BC), one of the most frequent humantumors, is genetically and histologically heterogeneous. Treatment options can be adapted according to BC subtype. Still, research is necessary to characterize BC biology better and to study potential new treatment options. Murine BC-cell lines can be used as model systems in this respect. RESULTS: Here for the first time murine BC-cell line JC was cytogenomically characterized as being complex rearranged and near-tetraploid. Multicolor banding and array comparative genomic hybridization were applied and the result was in silico translated to the human genome. CONCLUSIONS: Even though being commercially available, cell line JC was yet not much included in BC-research, most likely due to a lack of cytogenomic data. Thus, here comprehensive data is provided on chromosomal aberrations, genomic imbalances and involved breakpoints of JC cell line. Also JC could be characterized as a model for BC of luminal B type, basal-like tumor rather than for luminal A type.
Authors: Leanne de Kock; Dominique Geoffrion; Barbara Rivera; Rabea Wagener; Nelly Sabbaghian; Susanne Bens; Benjamin Ellezam; Dorothée Bouron-Dal Soglio; Jessica Ordóñez; Stephanie Sacharow; Jose Fernando Polo Nieto; R Paul Guillerman; Gordan M Vujanic; John R Priest; Reiner Siebert; William D Foulkes Journal: Genes Chromosomes Cancer Date: 2018-02-10 Impact factor: 5.006
Authors: Hugo M Horlings; Carmen Lai; Dimitry S A Nuyten; Hans Halfwerk; Petra Kristel; Erik van Beers; Simon A Joosse; Christiaan Klijn; Petra M Nederlof; Marcel J T Reinders; Lodewyk F A Wessels; Marc J van de Vijver Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531